Publications Archives

Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing

2022-09-07T22:31:04-07:00June 24th, 2021|2021 Publications, Featured Publications, Publications|

Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma

2023-01-10T16:48:18-08:00April 28th, 2021|2022 Publications, Featured Publications, Publications|

Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

2021-04-27T17:17:21-07:00April 20th, 2021|2021 Publications, Publications|

Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers

2021-02-11T19:51:54-08:00November 25th, 2020|2020 Publications, Publications|

Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status

2021-02-11T19:57:34-08:00November 22nd, 2020|2020 Publications, Publications|

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

2021-02-17T18:10:07-08:00November 17th, 2020|2020 Publications, Featured Publications, Publications|

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

2021-02-11T20:05:42-08:00October 30th, 2020|2020 Publications, Publications|

Plasticity of the human IgM repertoire in response to long‐term spaceflight

2021-02-11T20:09:45-08:00October 13th, 2020|2020 Publications, Featured Publications, Publications|

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

2021-02-11T20:11:02-08:00October 8th, 2020|2020 Publications, Publications|

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

2021-02-11T20:13:51-08:00August 27th, 2020|2020 Publications, Publications|

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment

2021-02-11T20:26:38-08:00July 22nd, 2020|2020 Publications, Publications|

Evaluation of the polymerase chain reaction–based T-cell receptor β clonality test in the diagnosis of early mycosis fungoides

2021-02-11T21:43:52-08:00June 8th, 2020|2020 Publications, Publications|

Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing

2021-02-11T21:47:46-08:00May 19th, 2020|2020 Publications, Publications|

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

2021-02-15T19:48:14-08:00May 6th, 2020|2020 Publications, Publications|

Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

2021-02-11T21:50:38-08:00May 1st, 2020|2020 Publications, Publications|

Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status

2021-02-11T21:53:32-08:00April 1st, 2020|2020 Publications, Publications|

Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complications

2021-02-11T21:56:18-08:00March 1st, 2020|2020 Publications, Publications|

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

2021-02-11T21:58:45-08:00February 6th, 2020|2020 Publications, Publications|

Monitoring minimal residual disease in the bone marrow using next generation sequencing

2021-02-11T22:00:56-08:00January 17th, 2020|2020 Publications, Publications|

Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequence

2021-02-11T23:36:10-08:00November 13th, 2019|2019 Publications, Publications|

Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications

2021-02-11T23:40:44-08:00October 15th, 2019|2019 Publications, Publications|

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

2021-02-11T23:43:09-08:00October 1st, 2019|2019 Publications, Publications|

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

2021-02-15T20:01:10-08:00June 6th, 2019|2019 Publications, Publications|

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

2021-02-11T23:46:14-08:00March 21st, 2019|2019 Publications, Featured Publications, Publications|

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

2021-02-11T23:49:39-08:00August 25th, 2018|2018 Publications, Featured Publications, Publications|

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.